趋化因子GRO-a在肾透明细胞癌中的表达及意义

Expression and biological effects of GRO-a in primary clear-cell renal cell carcinoma

目的探讨趋化因子GRO-a在肾透明细胞癌中的作用。方法选取2013年1月至2017年8月台州市中西医结合医院诊治的46例肾透明细胞癌患者作为研究对象。将其设为实验组;另随机选取开放切除的正常肾组织的46例患者设为对照组。采用免疫组化方法检测两组患者GRO-a的表达。结果本研究中,实验组患者GRO-a蛋白的阳性例数为34例,阳性率为73.9%;对照组患者GRO-a蛋白的阳性例数为14例,阳性率为30.4%;实验组阳性率显著高于对照组,其差异具有统计学意义(χ^2=13.49,P<0.05)。实验组患者中,GRO-a表达的阳性率与患者性别、肿瘤数量、临床分期及有无淋巴结转移均无明显关系(均P>0.05),而与肿瘤初发与复发均有关系(均P<0.05)。结论肾透明细胞癌组织中GRO-a蛋白表达水平增加,针对GRO-a的免疫治疗潜力巨大、前景广阔,值得进一步研究。

Objective To investigate the potential roles of GRO-a in clear-cell renal cell carcinoma. Methods 46 patients with clear-cell renal cell carcinoma treated in Taizhou Integrated Chinese and Western Medicine Hospital from January 2013 to August 2017 were selected as subjects of study, and were divided into the experimental group. Other 46 patients who received open resection of normal kidney tissues were randomly selected as the control group. Immunohistochemistry was used to detect the expression of GRO-a in both groups. Results In this study, 34 cases in the experimental group were positive for GRO-a protein and the positive rate of GRO-a was 73.9%, 14 cases in the control group were positive for GRO-a and the positive rate of GRO-a was 30.4%.The positive rate of GRO-a was significantly higher in the experimental group than in the control group, and the difference was statistically significant(χ^2=13.49, P<0.05). In the experimental group, the positive rate of GRO-a was not significantly related to the sex of patient, the number of tumor, the clinical staging of tumor or whether there is lymph node metastasis(all P>0.05). It was associated with tumor incipience and relapse(all P<0.05). Conclusions The level of GRO-a expression in clear-cell renal cell carcinoma increases, therefore immunotherapy for GRO-a has a great potential and broad prospects and is worth further study.